- Home
- UNCY vs OPTN Comparison
UNCY vs OPTN Comparison
Compare UNCY & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- OPTN
- Stock Information
- Founded
- UNCY 2016
- OPTN 2010
- Country
- UNCY United States
- OPTN United States
- Employees
- UNCY N/A
- OPTN N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- OPTN Health Care
- Exchange
- UNCY Nasdaq
- OPTN Nasdaq
- Market Cap
- UNCY 70.3M
- OPTN 78.4M
- IPO Year
- UNCY 2021
- OPTN 2017
- Fundamental
- Price
- UNCY $0.62
- OPTN $6.38
- Analyst Decision
- UNCY Strong Buy
- OPTN Strong Buy
- Analyst Count
- UNCY 4
- OPTN 3
- Target Price
- UNCY $5.50
- OPTN $16.67
- AVG Volume (30 Days)
- UNCY 1.3M
- OPTN 60.7K
- Earning Date
- UNCY 11-13-2024
- OPTN 03-06-2025
- Dividend Yield
- UNCY N/A
- OPTN N/A
- EPS Growth
- UNCY N/A
- OPTN N/A
- EPS
- UNCY N/A
- OPTN N/A
- Revenue
- UNCY N/A
- OPTN $75,672,000.00
- Revenue This Year
- UNCY N/A
- OPTN $13.42
- Revenue Next Year
- UNCY N/A
- OPTN $38.54
- P/E Ratio
- UNCY N/A
- OPTN N/A
- Revenue Growth
- UNCY N/A
- OPTN 5.13
- 52 Week Low
- UNCY $0.20
- OPTN $4.82
- 52 Week High
- UNCY $1.82
- OPTN $31.50
- Technical
- Relative Strength Index (RSI)
- UNCY 40.04
- OPTN 49.78
- Support Level
- UNCY $0.61
- OPTN $5.16
- Resistance Level
- UNCY $0.73
- OPTN $6.97
- Average True Range (ATR)
- UNCY 0.07
- OPTN 0.66
- MACD
- UNCY -0.02
- OPTN 0.10
- Stochastic Oscillator
- UNCY 15.66
- OPTN 71.08
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.